Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX), a global innovator in drug-delivery platforms, has released the results of its annual meeting, which was held June 28, 2021. According to the announcement, the meeting began at 1 p.m. PT with 2,735,413 company shares represented either in person or by proxy; that number constituted 53.6% of the company’s issued share capital as of May 3, 2021. There were several matters voted upon during the meeting, including the election of Chris Bunka, John Docherty, Nicholas Baxter, Ted McKechnie and Albert Reese Jr. as directors, with the percent approving the elections ranging from 82.1% to 97.6%. In addition, more than 99% of those in attendance voted to appoint Davidson & Company LLP as auditors. More than 68% voted to approve an amendment to the company’s equity incentive plan for the issuance of an additional 249,143 common shares, and almost 86% voted to ratify the lawful actions of the directors for the past year.
To view the full press release, visit https://ibn.fm/6PXbz
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-virals, cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information about the company, please visit www.LexariaScience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment